Background

Uterine fibroids (UFs), known as uterine leiomyomas, are benign smooth muscle neoplasms of the uterus affecting women of reproductive age.\(^1\) UF occur in 70% of women by the onset of menopause.\(^2\) They are estimated to be clinically apparent in 25% of women of reproductive age.\(^3\) Although they are often asymptomatic, UF can cause symptoms such as menorrhagia, abnormal uterine bleeding, pelvic pain or pressure, infertility, and recurrent pregnancy loss.\(^4\) Larger fibroids sometimes push the bladder or bowel and cause an increased urge to urinate or digestion problems (constipation, pain), and cause obstruction of the ureters impending to the immediate treatment.\(^5\)

In clinical practice, for the treatment of fibroids, surgical treatments are used effectively. Surgical treatments are preferred as the last resort by the patients because none of the surgical treatments, other than hysterectomy, offer a recurrence-free survival.\(^6\) However, during the current practice, the authors themselves have been consulted by many patients who are afraid of surgery and want a medical treatment for the fibroids. Medical treatment seems easier to be adopted, inculcates less fear, and is on a cheaper side. This has led to the practicing physicians to prescribe certain drugs for selective treatment of fibroids. It

ABSTRACT

Background and Objectives: In India, the uterine fibroid is a common indication of hysterectomy. An effective option for medical treatment may decrease the morbidity associated with hysterectomy. We aimed to evaluate the effect of mifepristone (25 mg), progesterone antagonist, on uterine fibroids in perimenopausal women. Methods: Fifty-four perimenopausal women of age ≥18 years having symptomatic uterine fibroids were selected from Gynecology OPD and given 25 mg mifepristone once daily continuously for 2–4 cycles of 3 months each. Variables such as baseline fibroid size, position, and hemoglobin were measured and followed at 3, 6, 9, and 12 months. The data were entered in MS EXCEL spreadsheet and analysis was done using Statistical Package for Social Sciences (SPSS) version 21.0. A \(P\) value of <0.05 was considered statistically significant. Results: Majority were intramural fibroids (70.37%) followed by submucosal in 16.67%. Size of fibroids ranged from <3 to >7 cm; the majority of fibroids were in 5–7 cm size. No significant association of location with the size of fibroid was found. Out of 54 cases included in the study, change in size in uterine fibroids was observed in 98.14% cases. There was an increase in hemoglobin, from 8.6 g% at baseline to 9.7 g% at 12 months. Conclusion: Mifepristone resulted in a reduction in uterine fibroids size and an increase in hemoglobin at the end of 12 months. It may be an option for uterine leiomyoma treatment, as it is given orally, cost-effective and has minimal side effects.

Keywords: Fibroid, leiomyoma, medical management, mifepristone, uterine

Address for correspondence: Dr. Shalini Sobti, F-311, Sainik Colony, Jammu - 180 011, India. E-mail: meeta448@gmail.com

Received: 26-03-2020
Revised: 25-04-2020
Accepted: 08-05-2020
Published: 30-07-2020

How to cite this article: Gupta M, Jamwal N, Sabharwal S, Sobti S. A prospective interventional study to evaluate the effects of medical therapy (Mifepristone 25 mg) on the management of uterine fibroids. J Family Med Prim Care 2020;9:3230-5.
becomes essential to know the indications and the appropriate
dose to treat the patients with minimal side effects.

Such attempts to find the nonsurgical alternate to treat fibroids
has been searched for decades, which involved the use of both
progestins and estrogen-progesterin combinations; however,
their evidence of good response is lacking. Subsequently the
use of GnRH agonists and antagonists were found to be
efficacious but caused side effects with prolonged use of more
than 6 months restricting their use as an adjuvant treatment
before surgery with overall good results. Another benchmark
development is the use of steroidal drug which may function as
antiprogestins—Mifepristone.\[10\]

Mifepristone is a steroid drug that can inhibit the secretion
of progesterone through noncompetitive inhibition. It also
reduces the level of epidermal growth factor receptors in fibroid
tissue, inhibits the proliferation of tumor cells, thus inhibiting
the growth of fibroids.\[7,8\] Its effects on the endometrium as
selective progesterone receptor modulator are reversible and
without any serious changes. Studies evaluated the efficacy of
mifepristone in doses varying from 2.5 to 50 mg/day\[9–12\] and it
was observed that doses <10 mg had lesser efficacy, whereas a
higher dose of 25 mg daily was an effective dose for causing a
clinically significant (50%) reduction in leiomyoma volume.\[10,11,13\]
It showed that long-term medical treatment of uterine fibroids
is feasible today and more studies are needed to adjudicate on its
dosage, use, efficacy, and safety in the clinical practice.

Thus, we did this study to evaluate the effects of medical
therapy (mifepristone 25 mg) on the management of uterine
fibroids among perimenopausal women.

**Methods**

A prospective interventional study was conducted in the department
of Obstetrics and Gynecology over a period of 1 year (31st January
2019 to 30th January 2020) where women with uterine fibroids were
enrolled for medical management after informed medical consent.
The study was approved from the institutional ethical committee
of the hospital (ASCOMS/IEC/2018/316). A written informed
consent was taken from all the patients enrolled in the study as
per the inclusion and exclusion criteria.

**Sample size**

The study of Engman \textit{et al}[^14] observed that median (IQR) of
total myoma volume at baseline was 161 (111–209) and at the
end of the study was 106 (52–205). Taking these values as a
reference, the minimum required sample size with 95% power
of study and 5% level of significance is 39 patients. Taking lost
to follow-up as 20%, the total sample size to be taken is 49. To
reduce the margin of error, the sample size taken is 54.

**Inclusion criteria**

1) Patients with the age of 18 years and above
2) Diagnosed fibroid cases
3) Fibroid size ≥2.5 cm
4) Patients who accepted the use of nonhormonal contraceptive
5) Patients who agreed to have an ultrasound examination in
every follow-up or evaluation visit

**Exclusion criteria**

1. Pregnancy
2. Undiagnosed cause of irregular bleeding PV
3. Underlying any other metabolic, hepatic, or renal complication

All included participants underwent Pap smear (excluding
unmarried women), endometrial evaluation by Pipelle or
aspiration in all married women >35 years, Hb levels, CBC, S.
ferritin levels, TSH, serum prolactin levels, and TVS/USG for
fibroid size and location and the endometrial thickness <5 mm
on the day of start of therapy. The intervention included
mifepristone 25 mg, which was started from 5th day of the
periods continuously for 3 months. A break was given until
the subject has had her periods (for the endometrium to shed).
Again, it was started from the 5th day of next periods for
the next 3 months. Likewise, the therapy was given for a total
of 4 cycles maximum if required (12 months), according to
the size of the fibroid. Data pertaining to the demography,
investigation findings, and the fibroid were recorded and
analyzed.

The outcome measure was the reduction in the size of the uterine
fibroids during the course of the treatment from 3 months to
12 months, depending upon the individual and the size of the
fibroid.

**Statistical analysis**

Categorical variables were presented in number and
percentage (%), and continuous variables were presented as
mean ± SD and range. Qualitative variables were compared
using Chi-Square test. A \(P\) value of <0.05 was considered
statistically significant. The data were entered in MS EXCEL
spreadsheet and analysis was done using Statistical Package for
Social Sciences (SPSS) version 21.0.

**Results**

Mean age of the patients in the study was 45.26 years. Most of
the patients (35.19%) were of >45 years age, followed by 31.48%
patients in 36–45 years age group. Total 85.19% of patients were
married [Table 1].

Chief complaints of the study subjects were menorrhagia in
79.63% and heaviness in 5.56% of patients. Total 14.81% of
patients were asymptomatic [Figure 1].

The intramural fibroid was the most common (70.37%) followed
by submucosal (16.67%) and subserosal (12.96%) fibroids.
Size of most of the fibroids (33.33%) was 5–7 cm, followed
by 29.63% having tumor size 3–5 cm and 20.37% having
size <3 cm [Table 2].
There was no significant association of the location of different types of fibroids with the size of the fibroid ($P = 0.714$) [Table 3].

At 3 months, there was no change in size in 11.11% patients. At 12 months, one patient (1.85%) had no change in tumor size. At 3 months, 0.5–0.9 mm change was noted in 29.63% patients; total 24.07% patients had 0.5–0.9 mm change at 12 months. A change of 1–1.4 mm in size was noted in 38.89% patients at 3 months, which increased to 42.59% patients at 12 months. Change in size of 1.5–1.9 mm was in 14.81% patients at 3 months and in 16.67% patients at 12 months. More than 2 mm change was present in 5.56% patients at 3 months and 14.81% patients at 12 months [Table 4].

At presentation, mean hemoglobin was 8.6 (g%) that increased to 9.7 (g%) at 12 months after the medical treatment [Figure 2].

**Discussion**

Although curative treatment for UF relies on surgical therapies, medical treatments are considered as the first-line treatment to preserve fertility and avoid or delay surgery.\cite{15,16}

In the index study, we found that medical management (mifepristone 25 mg) was effective in reducing the size of the small to medium fibroids. Our findings are supported by a recent analysis in the treatment of UF over a period of 2004–2018 by data mining technology and the medication rule which showed that among the common clinical drugs including leuprolin (GnRH-a), danazol (androgen), gestrinone (progestin), mifepristone (progesterone receptor antagonist), and some cases of combination therapy, the clinical use of mifepristone was the commonest with mild drug reactions and thus was worthy of clinical use and application.\cite{11}

The substantial effects of mifepristone are based on the combination effects on the estrogen, progesterone, and androgen regulators. The reduction in size of fibroids with mifepristone can be attributed to the direct effect in decreasing the number of progesterone receptors, and creating an early follicular like hormonal environment, thus leading to inhibition of steroid-dependent growth of myoma. Mifepristone also results in delay or inhibition of ovulation; causing amenorrhea and reduction of blood loss. It also causes direct suppressive effects on the endometrial vasculature by suppressing the stromal vascular endothelial growth factor (VEGF) release.\cite{10,13}

Fibroids is a growing problem among women after 35 years of age. The mean age of the patients in our study was 45.26 years with chief complaints of menorrhagia and heaviness. Among other studies, the mean age of the patients was 40.8 years in the study by Engman \textit{et al}; main symptoms reported were pelvic pain, bladder pressure, micturition problem, and low back pain.\cite{14} In a study by Jain, patients >35 years of age were included in the study; the main symptoms were menorrhagia, dysmenorrhea, and

| Table 1: Distribution of demographic characteristics n (%) |
| --- |
| Age in years |
| 18-25 | 6 | 11.11% |
| 26-35 | 12 | 22.22% |
| 36-45 | 17 | 31.48% |
| >45 | 19 | 35.19% |
| Mean±SD | 45.26±10.93 |
| Range | 19-55 |
| Marital status |
| Married | 46 | 85.19% |
| Unmarried | 8 | 14.81% |

| Table 2: Distribution of location and size of fibroid n (%) |
| --- |
| Location |
| Subserosal | 7 | 12.96% |
| Intramural | 38 | 70.37% |
| Submucosal | 9 | 16.67% |
| Size (in cm) |
| <3 | 11 | 20.37% |
| 3-5 | 16 | 29.63% |
| 5-7 | 18 | 33.33% |
| >7 | 9 | 16.67% |

**Figure 1:** Distribution of chief complaints of study subjects

**Figure 2:** Trend of hemoglobin of study subjects
Table 3: Association of location with size of fibroid

| Location       | Size          | n  | P       | Test performed  |
|----------------|---------------|----|---------|-----------------|
|                | <3 (n=9)      |    |         |                 |
| Subserosal     | 2 (22.22%)    |    |         |                 |
| Intramural     | 6 (66.67%)    |    |         |                 |
| Submucosal     | 1 (11.11%)    |    |         |                 |
| Total          | 9 (100.00%)   |    |         |                 |
|                | 3-5 (n=18)    |    |         |                 |
| Subserosal     | 2 (11.11%)    |    |         |                 |
| Intramural     | 13 (72.22%)   |    |         |                 |
| Submucosal     | 3 (16.67%)    |    |         |                 |
| Total          | 18 (100.00%)  |    |         |                 |
|                | 5-7 (n=13)    |    |         |                 |
| Subserosal     | 1 (7.69%)     |    |         |                 |
| Intramural     | 8 (61.54%)    |    |         |                 |
| Submucosal     | 4 (30.77%)    |    |         |                 |
| Total          | 13 (100.00%)  |    |         |                 |
|                | >7 (n=14)     |    |         |                 |
| Subserosal     | 2 (14.29%)    |    |         |                 |
| Intramural     | 11 (78.57%)   |    |         |                 |
| Submucosal     | 1 (7.14%)     |    |         |                 |
| Total          | 14 (100.00%)  |    |         |                 |

Table 4: Change in size of fibroid at different time intervals

| Time intervals | 3 months (n=54) | 6 months (n=54) | 9 months (n=54) | 12 months (n=54) |
|----------------|-----------------|-----------------|-----------------|------------------|
| No change in size | 6 (11.11%)     | 3 (5.56%)       | 2 (3.70%)       | 1 (1.85%)        |
| 0.5-0.9 mm      | 16 (29.63%)     | 12 (22.22%)     | 12 (22.22%)     | 13 (24.07%)      |
| 1-1.4 mm        | 21 (39.89%)     | 27 (50.00%)     | 27 (50.00%)     | 23 (42.59%)      |
| 1.5-1.9 mm      | 8 (14.81%)      | 6 (11.11%)      | 7 (12.96%)      | 9 (16.67%)       |
| >2 mm           | 3 (5.56%)       | 6 (11.11%)      | 6 (11.11%)      | 8 (14.81%)       |

Pressure symptoms.[10] Mean age was 38.47 years in the study by Seth et al.; abnormal and excessive uterine bleeding (AUB) was the commonest problem reported, followed by heaviness in lower abdomen and pain for which they came to the hospital.[13] Raghav et al. reported that the mean age of the patients was 39.40 years with main symptoms being menorrhagia followed by those having polymenorrhea, intermenstrual bleeding, polymenorrhagia, abdominal pain, and dysmenorrhea.[11]

The fibroids ranged in size from <3 cm to >7 cm. As compared to our study, Raghav et al. reported that mean size was 42,599 mm³, in the range of 2,400–205,920 mm³.[17] In a study by Kulshrestha et al.,[10] at enrolment, myoma volume was 176,800 mm³. Seth et al. reported a much higher volume of myoma (143,958 mm³).

On advocating treatment with mifepristone 25 mg, no reduction in size was seen in one of the fibroids in the duration of 12 months. The increased duration of the medical treatment led to an increased reduction in the size of the fibroid. At 12 months after treatment, >2 cm reduction in size was found to be increased as compared to 3-month, 6-month, and 9-month duration. As compared in Saxena et al. (2019), there was 85.08% reduction in multiple myomas and 79.11% reduction in single myomas.[14]

An increase in hemoglobin was found after 12 months of treatment as compared to baseline. Our results are comparable to that of previous studies. Kulshrestha et al. and Jain reported that there was a significant rise in hemoglobin levels with a dose of 25 mg (P < 0.05).[9,13]

The duration of treatment with mifepristone has been a variable factor depending upon the dose of mifepristone. Two doses have been tried 10 mg and 25 mg. The previous studies with mifepristone reported lesser efficacy with doses of 10 mg. It was concluded that for causing a clinically significant (50%) reduction in leiomyoma volume, an effective dose was 25 mg daily.[13] Saxena et al. (2019) found both doses to be effective in the reduction of myoma size, with 25 mg showing better pain reduction and overall symptoms improvement in case of failure in response with 10 mg.[10]

Jain studied the effect of mifepristone in the reduction of symptoms in leiomyomata in perimenopausal women. When mifepristone was continued, symptoms in both premenopausal and perimenopausal women were considerably improved.[15] The decrease in myoma size was statistically significant. Mukherjee and Chakraborty evaluated the efficacy of daily administration of 25 mg mifepristone in treating uterine leiomyoma. A 47% reduction in the leiomyoma volume and a 53% reduction in the uterine volume were found. Improvement in symptoms was also found. After treatment, 75.7% of patients became amenorrhoeic.[16]

Overall, mifepristone 25 mg seems better among the various doses in the effective management of fibroids without significant side effects. Some of the prior studies examined and validated the effectiveness of mifepristone 25 mg dose in ameliorating the symptoms and reduction in the size of uterine fibroids.[9,14,18,19]

Among the alternative treatments of uterine fibroids, uterine arterial embolization (UAE) has shown good clinical results in the treatment of uterine bleeding, uterine cancer as well as adenomyosis, and other uterine diseases. In a recent published case-control study (2019),[18] it was found that mifepristone and surgery and better options as compared to UAE. The authors found that the reduction in fibroid volume, average blood flow, peak systolic velocity, and thickest artery diameter were more with mifepristone as compared to UAE. The limitations of UAE procedure stem from the fact that ischemia concurrent to embolization results in further secretion of vascular growth factors in the local area resulting in increased growth of the fibroids.

Because of the increasing demands for postoperative quality of life and reproductive function, the majority of the patients select approaches that can maintain the uterus while achieving therapeutic effects.[12] Thus, the role of medicinal drugs becomes important in this regard.

**Why there is a current need of alternate medical treatment?**

Although fibroids are benign, the associated complications may vary from intermittent bleedings to continuous bleedings, from...
single pain episodes to severe pain, dysuria, constipation, chronic bladder, and bowel spasms with rare occurrence of peritonitis. Metro- and menorrhagia also cause infertility.[23] Thus, it needs to be judiciously managed on an individual symptomatic basis. The present surgical treatments are expensive and approximately one-third of the hysterectomies are due to fibroids. Removal of a uterus negatively affects a woman in terms of her mental and physical well-being even after treatment of the pathology. This makes it vital to develop and effectively use medical alternatives with the goals of fibroid reduction and fertility preservation.[23]

Sometimes, the decision to operate and medically manage may complicate the situation from the patient’s point of view. However, studies such as ours may help to clarify the individual dilemma in quite a few cases and help the doctor and the patient choose the best treatment for themselves.

**Limitations of the study**
The study has limitations. The outcomes of the medical management were not compared with the surgery outcomes. Even variable doses of mifepristone were not compared during the study.

However, the main strength of the study was the long follow-up (12 months) of the patients to monitor the size of the fibroids. And above all, the results showed that fibroids can be medically managed with 25 mg of mifepristone with minimal side effects.

**Conclusion**
Mifepristone caused a reduction in the size of uterine fibroids in 98.14% cases and a simultaneous increase in hemoglobin levels till the end of 12 months. Thus, mifepristone 25 mg is effective in reducing the size or complete curing of the fibroids and can be used as a surgical substitute in patients who have fibroid associated anemia, small to medium fibroids, women who want to preserve uterus and in cases where leiomyoma are unresectable, or surgery is difficult.

**Key points**
1. Mifepristone is a safe medical alternative to the surgical management of uterine fibroids.
2. The dosage of 25 mg is appropriate for the significant reduction in the size of the fibroids in the follow-up period of 1 year.
3. The routine use of medical management of fibroids shall make women fearless in addressing their complaints related to fibroids and beginning an early intervention.

**Declaration of patient consent**
The authors certify that they have obtained all appropriate patient consent forms. In the form, the patients have given their consent for their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

**Financial support and sponsorship**
Nil.

**Conflicts of interest**
There are no conflicts of interest.

**References**
1. Boosz AS, Reimer P, Matzko M, Romer T, Muller A. The conservative and interventional treatment of fibroids. Dtsch Arztebl Int 2014;111:877–83.
2. Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet 2020;149:3–9.
3. Taylor DK, Holthouse K, Segars JH, Leppert PC. Recent scientific advances in leiomyoma (uterine fibroids) research facilitates better understanding and management. F1000Res 2015;4(F1000 Faculty Rev):183.
4. Shen Q, Hua Y, Jiang W, Zhang W, Chen M, Zhu X. Effects of mifepristone on uterine leiomyoma in premenopausal women: A meta-analysis. Fertil Steril 2013;100:1722–6.
5. Khan AT, Shehmar M, Gupta JK. Uterine fibroids: Current perspectives. Int J Womens Health 2014;6:95–114.
6. Farris M, Bastianelli C, Rosato E, Brosens I, Benagiano G. Uterine fibroids: An update on current and emerging medical treatment options. Ther Clin Risk Manag 2019;15:157–78.
7. Raghav V, Singh Y, Shankar P, Dixit RK. Role of mifepristone in conservative management of fibroid uterus. World J Pharm Sci 2016;4:118–24.
8. Liu C, Lu Q, Qu H, Geng L, Bian M, Huang M, et al. Different dosages of mifepristone versus enantone to treat uterine fibroids: A multicenter randomized controlled trial. Medicine (Baltimore) 2017;96:e6124.
9. Kulshrestha V, Kriplani A, Agarwal N, Sareen N, Garg P, Hari S, et al. Low dose mifepristone in medical management of uterine leiomyoma—an experience from a tertiary care hospital from north India. Indian J Med Res 2013;137:1154–62.
10. Saxena R, Goyal R, Jain R. Effects of low dose oral mifepristone on uterine fibroids. Indian Obs Gyn 2019;9:38–42.
11. Xuan J, Deng G, Liu R, Chen X, Zheng Y. Analysis of medication data of women with uterine fibroids based on data mining technology. J Inf Pub Health 2019. doi:10.1016/j.jiph.2019.07.017.
12. Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: A randomised double-blind placebo-controlled clinical trial. Aust N Z J Obstet Gynaecol 2009;49:77–83.
13. Murphy AA, Morales AJ, Kettel LM, Yen SSC. Regression of uterine leiomyomata to the antiprogestosterone RU 486 dose response effect. Fertil Steril 1995;64:187–90.
14. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod 2009;24:1870–9.
15. Jain D. Mifepristone therapy in symptomatic leiomyomata using a variable dose pattern with a favourable outcome. J Midlife Health 2018;9:65-71.
16. Sohn GS, Cho S, Kim YM, Cho CH, Kim MR, Lee SR; Working Group of Society of Uterine Leiomyoma. Current medical treatment of uterine fibroids. Obstet Gynecol Sci 2018;61:192-201.
17. Seth S, Goel N, Singh E, Mathur AS, Gupta G. Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal woman. J Midlife Health 2013;4:22-6.
18. Mukherjee S, Chakraborty S. A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri. Niger Med J 2011;52:150-2.
19. Sankaran S, Manyonda IT. Medical management of fibroids. Best Pract Res Clin Obstet Gynaecol 2008;22:655-76.
20. Wang M, Shang C, Sun Q, Fang J, Li T. Effect of mifepristone combined with interventional embolization on patients with uterine fibroids. Int J Clin Exp Med 2019;12:10816-24.
21. De La Cruz MS, Buchanan EM. Uterine fibroids: Diagnosis and treatment. Am Fam Physician 2017;95:100-7.
22. Mettler L, Schollmeyer T, Tinelli A, Malvasi A, Alkatout I. Complications of uterine fibroids and their management, surgical management of fibroids, laparoscopy and hysteroscopy versus hysterectomy, haemorrhage, adhesions, and complications. Obstet Gynecol Int 2012;2012:791248.
23. Dolmans MM, Donnez J, Fellah L. Uterine fibroid management: Today and tomorrow. J Obstet Gynaecol Res 2019;45:1222-9.